Rehovot (Israel), April 26, 2010

Foamix Ltd., a leading developer of topical products, which can be used for dermatological, gynecological and ophthalmic applications, today announced that the United States Patent Office has granted the company a fourth patent, protecting its Oil-Gel™ drugs.

United States Patent No. 7,682,623, entitled “Pharmaceutical composition for topical application”, covers unique oil-based gel compositions that can be used to treat a wide range of diseases and disorders.

"This patent grant lends additional strength to Foamix’s patent portfolio and enhances the position of our multiple technologies and delivery systems," stated Dr. Dov Tamarkin, CEO of Foamix. "Moreover, the patent will help Foamix to build new strategic partnerships and provide licensing opportunities to develop unique dermatological and ophthalmologic drugs," he added.

Foamix’s OilGel™ technology is intended as a convenient and easy delivery system of medicated actives for application to the skin and to mucosal membranes including the ocular mucosa and the vagina.

OilGel™ -based products exhibit a semi-solid state but transform to a readily spreadable liquid state upon applying onto the skin, which can be rapidly absorbed. Likewise this property allows for easy ocular application of compositions as a semi-solid ophthalmic drug preparation, which has marked advantages over conventional eye drops and ointments.

Being water-free, and having a semi-solid gel rheology, the OilGel™ products can accommodate one or more water-sensitive, for example, pH sensitive drugs. The granted claims are directed inter alia , to pharmaceutical compositions comprising a carrier and therapeutically effective amounts of drugs. Various drugs are claimed including antibiotics, antifungals, antiviral agents, non-steroidal anti-inflammatory drugs, immunosupressants, anti-inflammatory agents, vitamin derivatives and corticosteroids.

About Foamix:

Headquartered in Rehovot, Israel, Foamix Ltd. a leading developer of topical and mucosal foams and Oil Gel™ formulations, which can be used for dermatological, gynecological and ophthalmic applications. Foamix’s state-of-the-art foams and OilGel™ formulations provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation.

To date, Foamix has twenty two issued patents worldwide covering its foam and OilGel™ technology platforms, including 7 issued patents in the United States. The company further has over 150 pending patent applications worldwide, of which more than 50 are filed in the U.S.

For additional information please visit www.foamix.co.il